Drug intelligence / Profile preview

DMab-1

Development stage: Preclinical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

DMab-1 is a monoclonal antibody that specifically recognizes the GalNAc beta1-4(NeuAc alpha 2-3)Gal-terminal epitope, which is common to ganglioside GM2 and GalNAC-GD1a. It has been shown to induce severe necrosis in GM2-rich cultures of human glioma cell lines in vitro. The antibody's binding affinity is influenced by the fatty acid composition of the GM2 ganglioside. DMab-1 is part of a series of five IgM monoclonal antibodies (DMAb-1 through DMAb-5) developed to investigate GM2 expression in gliomas and other neuroectodermal tumors.

Targets

GM2 (Ganglioside GM2)

Beyond the preview

Go deeper on DMab-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DMab-1.

Explore the full profile